Atara Biotherapeutics(ATRA) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress Atara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufacturing and supply of tabelecleucel for development and commercialization worldwide Atara expects to reduce its operating expenses year-over-year by approximately 65% in 2025 as a result of implemented cost reduction initiatives • Atara has paused development of its CAR T progra ...